MRI for Assessing Prostate Cancer Response
NCT01607008 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38
Last updated 2025-11-28
Summary
Prostate cancer is one of most common cancers in America, affecting 1 in 6 men. External beam radiation therapy is one of the common methods to treat prostate cancer. Although radiotherapy is effective, side effects to the adjacent normal organs limit the therapeutic ratio. Those side effects are usually associated with the radiation damage of the normal tissue surrounding prostate, e.g. bladder, urethra and rectum etc. Both effectiveness and the side effects of radiation treatment are often accessed after whole course of radiotherapy, which makes the early intervention difficult. The current research project is a feasibility study of utilizing advanced magnetic resonance imaging (MRI) techniques to access radiotherapy treatment response of prostate cancer during and right after radiotherapy.
Many advanced MRI techniques, e.g. spectroscopy (MRS), diffusion-weighted (DWI), dynamic contrast enhanced (DCE) perfusion weighted images, have been used in radiology departments for diagnostic purpose. This research project is to study the feasibility of using advanced MRI sequences to monitor tissue response during and after radiotherapy. The tissue changes revealed from MRI can provide physicians early information on possible tumor recurrence and normal tissue toxicity, therefore, the early intervention may be possible to spare normal tissue and cure the patient. The project is designed to combine several different advanced MRI imaging techniques systematically to study tissue changes during radiotherapy, which has not been seen elsewhere to date.
Another important goal of this research project is to study the feasibility of associating functional MRI with radiation treatment dose distribution. Tissue response during radiation treatment depends on dose. The functional MRI can provide more information than simple anatomic information. Mapping the functional MRI spatially and associating them with 3D dose distribution in radiation treatment planning system is one important step to quantitative assess the relationship between radiation treatment and tissue changes due to the radiation.
Conditions
Interventions
- OTHER
-
MRI imaging
3 total MRI imaging studies: 1. pre standard radiation treatment 2. during standard radiation treatment 3. post standard radiation treatment
Sponsors & Collaborators
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
lead OTHER
Principal Investigators
-
Danny Song, M.D. · The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-11-16
- Primary Completion
- 2027-12-31
- Completion
- 2028-12-31
Countries
- United States
Study Locations
More Related Trials
-
NEWPROMRI-PATHWAY - A New Prostate Magnetic Resonance Imaging (MRI) Pathway
NCT06672926 ·Status: RECRUITING
-
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
NCT01913197 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
NCT04692675 ·Status: RECRUITING ·Phase: NA
-
Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
NCT02470910 ·Status: COMPLETED ·Phase: NA
-
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
NCT03160794 ·Status: RECRUITING ·Phase: NA
-
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer
NCT00082147 ·Status: COMPLETED ·Phase: NA
-
Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration
NCT00987376 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
NCT04997018 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Localising Occult Prostate Cancer Metastases With Advanced Imaging TEchniques
NCT02935816 ·Status: UNKNOWN
-
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
NCT01138527 ·Status: COMPLETED
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
NCT05710380 ·Status: RECRUITING ·Phase: NA
-
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
NCT03181867 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
NCT03697148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
NCT02420977 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
NCT03619655 ·Status: TERMINATED ·Phase: PHASE1
-
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
NCT06391034 ·Status: RECRUITING ·Phase: PHASE2
-
PET/MRI in Patients With Suspected Prostate Cancer
NCT02659527 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
NCT03439033 ·Status: TERMINATED ·Phase: PHASE2
-
Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies
NCT04541030 ·Status: ACTIVE_NOT_RECRUITING
-
MRI in Diagnosing Prostate Cancer
NCT01292291 ·Status: UNKNOWN ·Phase: NA
-
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
NCT04521894 ·Status: UNKNOWN
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
NCT03933670 ·Status: RECRUITING ·Phase: PHASE2
-
CEUS Targeted Biopsies Compared to mpMRI Targeted and Systematic Biopsies for the Detection of Prostate Cancer
NCT02831920 ·Status: UNKNOWN ·Phase: NA
-
MRI/MRSI in Risk Assessment of Prostate Cancer Patients
NCT00582543 ·Status: COMPLETED ·Phase: NA
-
Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
NCT05078151 ·Status: UNKNOWN ·Phase: NA